Company profile: Applied Therapeutics
1.1 - Company Overview
Company description
- Provider of drug development targeting molecules/pathways in fatal or debilitating diseases, with programs: govorestat for Galactosemia (pediatric Phase 3 completed; MAA validated; NDA accepted; PDUFA date set), SORD Deficiency (positive pilot; ongoing Phase 3), PMM2-CDG (Phase 2-ready; Expanded Access), AT-001 for Diabetic Cardiomyopathy/Peripheral Neuropathy (Phase 3), and AT-003 for Diabetic Retinopathy (Phase 1-ready).
Products and services
- AT-001 for Diabetic Cardiomyopathy: Phase 3 therapy with topline data available, focusing on cardiac outcomes in diabetic patients within an ongoing controlled trial framework
- Govorestat for Galactosemia: NDA-accepted therapy with a PDUFA date set, completed pediatric Phase 3 outcomes trial, and MAA validated for regulatory review in galactosemia
- Govorestat for SORD Deficiency: Phase 3 candidate with positive pilot study and 12-month interim efficacy data, ongoing study evaluating functional outcomes in SORD Deficiency
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Applied Therapeutics
Vidacare
HQ: United States
Website
- Description: Provider of intraosseous access devices for diagnostic, monitoring, and therapeutic applications. Develops, manufactures, and markets the EZ-IO Product System, designed to provide controlled vascular access through the intraosseous route.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vidacare company profile →
Tenaya Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage gene and small molecule therapies for heart diseases, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy, TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, and TN-301, an HDAC6 inhibitor for heart failure with preserved ejection fraction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tenaya Therapeutics company profile →
Intelesens
HQ: United Kingdom
Website
- Description: Provider of intelligent, wearable, non-invasive, wireless vital signs monitoring devices for hospital and home patient monitoring, leveraging proprietary high-sensitivity arrhythmia and respiratory algorithms, and offering defibrillation and ECG electrodes plus custom electrode design, prototyping, and end-to-end manufacturing compliant with international regulatory standards.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intelesens company profile →
CryoCath
HQ: Canada
Website
- Description: Provider of cryoablation catheter systems for treating cardiac arrhythmias, tumors, and other obstructions, comprising flexible, steerable catheters supported by electromechanical consoles that deliver and recover refrigerants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CryoCath company profile →
Acron Genomics
HQ: United Kingdom
Website
- Description: Provider of novel biotechnology platform development and commercialization in the life sciences, and of the introduction and development of promising new pharmaceutical compounds. U.S. publicly traded (OTC Markets/AGNM).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acron Genomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Applied Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Applied Therapeutics
2.2 - Growth funds investing in similar companies to Applied Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Applied Therapeutics
4.2 - Public trading comparable groups for Applied Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →